Manchester, UK - 14th October 2008 Tepnel Life Sciences PLC (AIM: TED) today announced that it has expanded its molecular genetic services offering through the addition of Illumina's iScan System, a next-generation scanner that provides researchers conducting genetic variation studies with significantly greater throughput and application diversity.  This announcement marks the first anniversary of Tepnel's new pharmaceutical services facility and makes Tepnel the first commercial provider of iScan services within the UK.

Combined with Tepnel's established range of upstream and downstream genetic capabilities, the Company now offers a full suite of complementary services from DNA extraction through to Bioinformatics.  Illumina's iScan platform supports both human and non-human applications and is capable of generating up to 225 million genotypes per day.

Tepnel also has a variety of other platforms and techniques for SNP-based investigations for both human and non-human research and clinical applications.  This breadth of service enables Tepnel to provide a complete solution from DNA extraction through to SNP genotyping and DNA sequencing, all undertaken in accordance with Good Laboratory Practice (GLP).

 "Tepnel can offer customers a broad portfolio of innovative genetic analysis assays some of which are supported on our new high-throughput iScan reader," said David Scott, General Manager of Tepnel's Livingston facility. "This new addition to our service opens up the possibility to our customers of whole genome association, focused content analysis, copy number variation analysis and, epigenetics on both human and non-human samples, all within a regulatory compliant environment."